Detalhe da pesquisa
1.
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
N Engl J Med
; 389(19): 1778-1789, 2023 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870949
2.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
J Immunol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758119
3.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
4.
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
N Engl J Med
; 384(22): 2102-2114, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077643
5.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
6.
Removal of α1-Microglobulin Using Post-Dilution Online Hemodiafiltration with Polymethylmethacrylate Membrane: An Open-Label, Single-Arm Study.
Blood Purif
; 53(2): 123-129, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939684
7.
Arteriolar hyalinization at 0-hour biopsy predicts long-term graft function in deceased kidney transplantation.
Int J Urol
; 31(3): 287-294, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062869
8.
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Int J Urol
; 31(3): 265-272, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110838
9.
MicroRNAs as Potential Regulators of GSK-3ß in Renal Cell Carcinoma.
Curr Issues Mol Biol
; 45(9): 7432-7448, 2023 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37754254
10.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099926
11.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Oncologist
; 28(4): 333-340, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576173
12.
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Cancer Immunol Immunother
; 72(6): 1903-1915, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729213
13.
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Future Oncol
; 19(6): 413-426, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36919916
14.
The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
Jpn J Clin Oncol
; 53(8): 730-737, 2023 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37151051
15.
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Jpn J Clin Oncol
; 53(1): 16-25, 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300304
16.
Hyporesponsiveness against donor's ABO antigens of renal grafts after ABO-incompatible kidney transplantation.
Clin Exp Nephrol
; 27(1): 89-95, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209259
17.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Int J Clin Oncol
; 28(2): 289-298, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534263
18.
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Int J Clin Oncol
; 28(3): 416-426, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595123
19.
Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update.
Int J Urol
; 30(10): 808-817, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37278492
20.
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.
Int J Urol
; 30(9): 788-796, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528632